Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
Charalampos Charalampous(The Ohio State University Wexner Medical Center), Shaji Kumar(Mayo Clinic in Arizona), Francis K. Buadi, Morie A. Gertz(Mayo Clinic in Arizona), Prashant Kapoor, Utkarsh Goel, Rahma Warsame, Taxiarchis Kourelis, Martha Q. Lacy, William J. Hogan(Mayo Clinic), Angela Dispenzieri(WinnMed), Suzanne R. Hayman, David Dingli
Cited by 5
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k